ProMIS Neurosciences ( (PMN)) has provided an announcement. On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...

Background: The Patient-Reported Outcomes Measurement Information System 29-item (PROMIS-29) profile is commonly used to measure patients’ self-reported health status. This study examined the ...

Objectives Characterise the health status of patients newly consulting an orthopaedic specialist across eight clinical subspecialties. Design Retrospective cohort. Setting 18 orthopaedic clinics, ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Hydra is full-featured lightweight library which allows you to write better async code in Swift 3.x/4.x. It's partially based on JavaScript A+ specs and also implements modern construct like await (as ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. According to projections from 4 analysts, the average ...

(RTTNews) - ProMIS Neurosciences (PMN) announced the FDA has granted Fast Track designation to PMN310, the company's lead therapeutic candidate in development for the treatment of Alzheimers disease.

Investigators found that making a few changes to a common patient-reported outcomes assessment improved its validity in patients with Duchenne muscular dystrophy. A new customized version of a common ...

Background: Inflammatory bowel disease (IBD) may adversely affect physical, psychological, and social well-being. Integrating patient-reported outcomes (PROs) into clinical practice is crucial for ...